Browsing Other ICR Research by title
Now showing items 342-361 of 612
-
Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.
(ELSEVIER SCIENCE INC, 2017-06-17)Triple-negative breast cancer is a heterogeneous disease and specific therapies have not been available for a long time. Therefore, conventional chemotherapy is still considered the clinical state of the art. Different ... -
Molecular mechanisms of PARP inhibitor sensitivity in primary triple negative breast cancer
(Institute of Cancer Research (University Of London), 2021-08-31)Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup harbouring evidence of defective homologous recombination (HR) DNA repair. At present there are no biomarkers available in ... -
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.
(AMER ASSOC CANCER RESEARCH, 2023-10-13)PURPOSE: We present the results of a post hoc tumor tissue analysis from the phase 3 MILO/ENGOT-ov11 study (NCT01849874). PATIENTS AND METHODS: Mutation/copy-number analysis was performed on tissue obtained pre-randomization. ... -
MR-guided radiotherapy for prostate cancer: state of the art and future perspectives.
(BRITISH INST RADIOLOGY, 2022-03-01)Advances in radiotherapy technology have increased precision of treatment delivery and in some tumour types, improved cure rates and decreased side effects. A new generation of radiotherapy machines, hybrids of an MRI ... -
MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis
(American Society of Hematology, 2022-02-03)<jats:title>Abstract</jats:title> <jats:p>The chronic phase of chronic myeloid leukemia (CP-CML) is characterized by the excessive production of maturating myeloid cells. As CML stem/progenitor cells (LSPCs) ... -
Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
(2018-07)Background Men with suspected prostate cancer usually undergo transrectal ultrasound (TRUS)-guided prostate biopsy. TRUS-guided biopsy can cause side effects and has relatively poor diagnostic accuracy. Multiparametric ... -
Multiple myeloma: family history and mortality in second primary cancers.
(NATURE PUBLISHING GROUP, 2018-08-07) -
Multiple paternity in superfetatious live-bearing fishes.
(WILEY, 2022-05-25)Superfetation, the ability to carry several overlapping broods at different developmental stages, has evolved independently multiple times within the live-bearing fish family Poeciliidae. Even though superfetation is ... -
MUTYH-Associated Polyposis: The Irish Experience>.
(2016-12-12)MUTYH is involved in DNA damage repair. Bi-allelic MUTYH mutations predispose to polyposis and gastrointestinal malignancies, distinct genetically from autosomal dominant familial adenomatous polyposis coli. Two common ... -
National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meeting.
(WILEY, 2018-07-01)OBJECTIVES: To identify areas of agreement and disagreement in the implementation of multi-parametric magnetic resonance imaging (mpMRI) of the prostate in the diagnostic pathway. MATERIALS AND METHODS: Fifteen UK experts ... -
National survey of fiducial marker insertion for prostate image guided radiotherapy.
(ELSEVIER SCI LTD, 2018-11-01)INTRODUCTION: In the United Kingdom fiducial marker IGRT is the second most common verification method employed in radical prostate radiotherapy yet little evidence exists to support centres introducing or developing this ... -
Natural Selection in Cancer Biology: From Molecular Snowflakes to Trait Hallmarks
(2017-02)Evolution by natural selection is the conceptual foundation for nearly every branch of biology and increasingly also for biomedicine and medical research. In cancer biology, evolution explains how populations of cells in ... -
Negative selection in tumor genome evolution acts on essential cellular functions and the immunopeptidome.
(BMC, 2018-05-31)BACKGROUND: Natural selection shapes cancer genomes. Previous studies used signatures of positive selection to identify genes driving malignant transformation. However, the contribution of negative selection against somatic ... -
Neuroblastoma in monozygotic twins - a case of probable twin to twin metastasis (vol 85, pg 493, 2001)
(NATURE PUBLISHING GROUP, 2002-05-20) -
New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer.
(ASSOC DEVELOPPEMENT COMMUNICATION CANCEROLOGIQUE, 2021-11-01)Since the proof of concept of synthetic lethality between poly(ADP-ribose) polymerase inhibition and loss of BRCA1/2 homologous recombination (HR) function in preclinical models and early phase clinical trials, poly(ADP-ribose) ... -
The next wave of interactomics: Mapping the SLiM-based interactions of the intrinsically disordered proteome.
(CURRENT BIOLOGY LTD, 2023-06-01)Short linear motifs (SLiMs) are a unique and ubiquitous class of protein interaction modules that perform key regulatory functions and drive dynamic complex formation. For decades, interactions mediated by SLiMs have ... -
Nipple sparing versus skin sparing mastectomy: a systematic review protocol.
(2016-05-20)Introduction Breast cancer has a lifetime incidence of one in eight women. Over the past three decades there has been a move towards breast conservation and a focus on aesthetic outcomes while maintaining oncological safety. ... -
Nipple-sparing mastectomy in women at high risk of developing breast cancer.
(2018-06)Nipple-sparing mastectomy is a valuable addition to the options available for women at high risk of developing breast cancer. In this review, we summarize current knowledge about the high-risk genes, BRCA1 , BRCA2 and TP53 ... -
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
<h4>Background</h4>First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previously ... -
Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
(2021-01-08)Purpose This study aimed to assess the efficacy of the combination of nivolumab (nivo) plus ipilimumab (ipi) as a first-line therapy with respect to the 12-month overall survival (OS) in patients with metastatic uveal ...